Bosulif® Clinical Papers

Please use the links below to access the Bosulif® clinical papers

1) Cortes JE et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. Journal of Clinical Oncology  2018; 36(3): 231-7.

Click here to download paper

This clinical paper has been certified by Pfizer Ltd. in accordance with the ABPI Code of Practice and contains promotional information and is intended for UK Healthcare Professionals. PP-BOS-GBR-0970. March 2020

2) Gambacorti-Passerini, C et al. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica 2018; 103(8): 1298–307.

Click here to download paper

This clinical paper has been certified by Pfizer Ltd. in accordance with the ABPI Code of Practice. and contains promotional information and is intended for UK Healthcare Professionals. PP-BOS-GBR-0978. March 2020

3) Gambacorti-Passerini, C et al. The role of bosutinib in the treatment of chronic myeloid leukaemia. Future Oncol. 2020; 16 (2): 4395-4408. 

Click here to download paper

This clinical paper has been certified by Pfizer Ltd. in accordance with the ABPI Code of Practice and contains promotional information and is intended for UK Healthcare Professionals. PP-BOS-GBR-0966. March 2020

Indication1:

BOSULIF® is indicated for the treatment of adult patients with:

  • Newly-diagnosed chronic phase (CP) Philadelphia chromosomepositive chronic myelogenous leukaemia (Ph+ CML)
  • CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options

Posology1:

  • Newly-diagnosed CP Ph+ CML: The recommended dose is 400 mg bosutinib once daily.
  • CP, AP, or BP Ph+ CML with resistance or intolerance to prior therapy: The recommended dose is 500 mg bosutinib once daily.

In clinical trials for both indications, treatment with bosutinib continued until disease progression or intolerance to therapy.

Reference:

1) BOSULIF® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/7943/smpc. Accessed: April 2020.

 

PP-BOS-GBR-0991. May 2020